Overview

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2015-12-28
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Liraglutide